Phrontline Biopharma, a next‑generation antibody‑drug conjugate (ADC) company, announced the close of an oversubscribed USD 60 million Pre‑A+ financing round led by Lapam Capital, with participation from Samsung Venture Investment Corporation, Shiyao Guofang Leading Fund, Hankang Capital, Songqing Capital, Jifeng Capital, Sino Biopharmaceutical, and continued support from existing shareholders Decheng Capital, Med‑Fine Capital, and Jianfa Capital. Proceeds will accelerate clinical development and international collaborations.
Financing Details
Item
Detail
Company
Phrontline Biopharma
Amount
USD 60 million (Series Pre‑A+)
Lead Investor
Lapam Capital
New Investors
Samsung Venture, Shiyao Guofang Leading Fund, Hankang Capital, Songqing Capital, Jifeng Capital, Sino Biopharmaceutical
Existing Investors
Decheng Capital, Med‑Fine Capital, Jianfa Capital (all increased stakes)
Use of Proceeds
Clinical advancement, international partnerships, platform expansion
Company Profile
Founded: 2022
Focus:Bispecific antibody‑drug conjugates (BsAb‑ADCs) and dual‑payload ADCs
Platform: Comprehensive ADC technology covering antibody discovery, linker‑payload design, site‑specific conjugation, and functional evaluation with proprietary IP
Pipeline: Nearly 10 innovative pipelines in precision oncology
Lead Program
Product
Target
Indication
Stage
Geography
TJ101
EGFR/B7‑H3 bispecific ADC
Solid tumors
Clinical enrollment
China & US (simultaneous)
Differentiation: Dual targeting may overcome resistance and improve tumor specificity
Regulatory Path: Simultaneous China/US filing strategy positions for potential global partnership
Market Context & Outlook
Metric
Value
Global ADC Market
$15.4 billion (2024)
Bispecific ADC Pipeline
<15% of ADC clinical candidates globally
China ADC Financing
$2.3 billion invested in 2024
Peak Sales Potential (TJ101)
$500‑700 million (if approved)
Competitive Landscape:
First‑mover advantage in EGFR/B7‑H3 ADC; rivals include MacroGenics (B7‑H3 programs) and AstraZeneca/Daiichi (EGFR ADCs)
Valuation: Post‑money valuation estimated at $250‑300 million , positioning Phrontline for Series B in H2 2026
International Strategy: Samsung Venture partnership may facilitate South Korean clinical sites and future global co‑development
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phrontline’s clinical development, platform expansion, and market potential. Actual results may differ materially due to risks including clinical trial outcomes, competitive dynamics, and fundraising conditions.-Fineline Info & Tech
By Fineline Cube 